Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The Early Access service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community. These articles are searchable and citable by their DOI (Digital Object Identifier).

The Monaldi Archives for Chest Disease is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one. The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2024 [Online ahead of print]

To cite this Article:

©The Author(s), 2024
Licensee PAGPress, Italy
Severe heart failure and intracardiac thrombosis: 
going beyond the appearance for diagnosis and treatments

Andrea Segreti,1,3 Sara Mastroberardino,1,2 Lorenzo Frau,1,2
Alessandro Appetecchia,1,2 Luca D’Antonio,1,2
Danilo Ricciardi,1,2 Gian Paolo Ussia,1,2 Francesco Grigioni1,2

1Research Unit of Cardiovascular Science, Department of Medicine and Surgery, Università
Campus Bio-Medico di Roma; 2Cardiology Unit, Fondazione Policlinico Universitario Campus
Bio-Medico, Rome; 3Department of Movement, Human and Health Sciences, University of
Rome “Foro Italico”, Italy

Correspondence: Andrea Segreti, Research Unit of Cardiovascular Science, Department of
Medicine and Surgery, Università Campus Bio-Medico di Roma, via Alvaro del Portillo 200,
00128 Rome, Italy.
E-mail: a.segreti@policlinicocampus.it

Contributions: all authors have contributed significantly and agree with the manuscript’s
content.

Conflict of interest: the authors declare no conflict of interest.

Ethics approval and consent to participate: institutional review board approval was not
required for this study as only de-identified compliant data were used in the analysis.

Patient consent for publication: informed consent was obtained from the patient for
anonymized information to be published in this article. The manuscript does not contain any
individual person’s data in any form.

Funding: none.

Availability of data and materials: all data underlying the findings are fully available.
Abstract
We describe the case of a 45-year-old female affected by asthma and nasal polyposis who presented to the emergency department because of worsening dyspnea and paresthesia of the left lower limb. Comprehensive instrumental examinations revealed the presence of severe left ventricle dysfunction, intra-cardiac thrombus, deep vein thrombosis, pulmonary embolism, lung infiltrates, polyserositis, and neurological involvements. Finally, the patient was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss syndrome, a rare vasculitis of small-medium blood vessels with several organ involvements. Treatment with anticoagulants, corticosteroids, and cyclophosphamide led to a significant clinical improvement. However, a subcutaneous cardiac defibrillator was implanted because of the persistence of severe left ventricular dysfunction and the high cardiovascular risk phenotype. Indeed, several cardiac manifestations may occur in EGPA, particularly in patients with anti-neutrophil cytoplasmic antibody-negative disease. Therefore, clinicians should have high clinical suspicion because cardiac involvement in EGPA results in a poor prognosis if not diagnosed and adequately treated.

Key words: eosinophilic granulomatosis with polyangiitis, dilated cardiomyopathy, cardiac thrombosis, hypereosinophilia, pulmonary infiltrates.

Introduction
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss syndrome, is a systemic syndrome characterized by eosinophil-rich granulomatous inflammation and necrotizing small-vessel vasculitis. It was first described in 1951 by Jacob Churg and Lotte Strauss in patients affected by asthma, hypereosinophilia, cardiac failure, and renal and neurological involvement [1]. EGPA’s estimated annual incidence is between 0.5 and 4.2 cases per million [2]. Due to its rarity and the ample clinical, laboratory, and pathological variability, it is essential to recognize this syndrome to start promptly adequate treatment; indeed, the disease is frequently characterized by heart and lung involvement with possible severe and fatal complications. In the present article, we describe a case of a 45-year-old female who presented to the Emergency Department because of worsening dyspnea, deep vein thrombosis, and left lower
limb paresthesia. Comprehensive clinical and instrumental evaluations led to a diagnosis of anti-neutrophil cytoplasmic antibodies (ANCA)-negative EGPA with critical cardiovascular, neurological, and respiratory involvement.

Case Report
A 45-year-old former smoker woman, affected by bronchial asthma and nasal polyposis, experienced gradually worsening dyspnea, hepatomegaly, and paresthesia on the left lower limb that was hot and edematous. A total body positron emission tomography/computed tomography showed left segmental pulmonary thromboembolism associated with patchy pulmonary infiltrations, pericardial and pleural effusions, cardiogenic liver cirrhosis, and thrombosis of the right uterine vein and left gonadal vein.

Therefore, she was admitted to the Emergency Department. At admission, general conditions were mediocre; blood pressure was 100/70 mmHg, heart rate 111 bpm, oxygen saturation 98% at room air, and blood temperature 36 C. Cardiac examination revealed paraasonic tones and no heart murmurs, while chest examination a plessic obtusity and loss of vesicular murmur on the pulmonary bases.

The admission electrocardiogram (EKG) showed sinus bradycardia, low QRS voltages in the peripheral leads, normal atrioventricular and intraventricular conduction, poor r-wave progression in the precordial leads, and diffuse repolarization abnormalities (Figure 1). The trans-thoracic echocardiography revealed a dilatated and hypokinetic left ventricle, thrombotic stratification at the apex, bi-atrial and bi-ventricular dilation, severe reduction of bi-ventricular global systolic function, and circumferential pericardial effusion not determining chambers compression (Figure 2). Blood test examination showed a severe eosinophilia (1900 cell/ul, relative value 11%), a marked increase of NT-Pro BNP (26200 pg/ml), and a mild increase of troponin I HS (56 pg/ml).

The patient was transferred to the coronary intensive care unit. The heart/coronary CT documented epicardial coronaries free from significant atheromatous pathology and confirmed the presence of endocavitary thrombosis. The cardiac magnetic resonance (CMR) better characterized the left ventricle thrombus and showed the presence of a dilated cardiomyopathy with a severe reduction in systolic biventricular function (left ventricular ejection fraction = 14%, right ventricular ejection fraction = 26%), late gadolinium enhancement (LGE) in the sub-endocardial area with diffuse involvement of the mid-apical
ventricular segments and in the infra-myocardial area at the level of the lower basal and mid-apical intraventricular septum (Figure 3).

The autoantibodies ANCA were negative. According to the ACR/EULAR 2022 criteria [3], in the presence of bronchial asthma, nasal polyposis, motoneuritis, and hypereosinophilia, a diagnosis of ANCA-negative EGPA with cardiac involvement was made.

Genetic testing was negative for FIP1L1-PDGFRA; Leiden V Factor, II factor, C and S protein mutations, and antiphospholipid antibodies were excluded. Therefore, anticoagulants and immunosuppression therapy with corticosteroids and cyclophosphamide were started. However, although medical treatment for ventricular dysfunction was optimized, the implantation of a subcutaneous cardiac defibrillator for primary prevention of arrhythmias was required, as the 2022 European Society of Cardiology (ESC) guidelines recommend [4].

**Discussion**

EGPA is a rare vasculitis of small-medium blood vessels occurring in patients with asthma and hyper-eosinophilia [2,5]. Histologically, it is characterized by necrotizing vasculitis and tissue eosinophil-rich granulomatous inflammation [5]. EGPA usually involves three steps that can also overlap [5]. The prodromic ‘allergic’ phase can last several years and is characterized by asthma [2]. The ‘eosinophilic’ phase is marked by blood hyper-eosinophilia, systemic involvement, and organ dysfunction. The ‘vasculitic’ phase (not present in all the patients) is characterized by clinical manifestations due to small-vessel vasculitis [5].

In addition to asthma, respiratory involvement included lung infiltrates (radiologically patchy, peripheral, and migratory), pleural effusions secondary to eosinophilic pleurisy or eosinophilic cardiomyopathy-associated congestive cardiac failure, chronic recurrent rhinosinusitis and nasal polyposis [2]. Other clinical manifestations may be possible, depending on vasculitic involvement of cardiovascular, neurological, renal, gastrointestinal, and dermatological organs.

Cardiac involvement is present in one-third of cases and may range from silent to severe forms; it is the most adverse prognostic indicator because it is associated with severe complications and disease relapse [2,5-7]. Approximately 50% of deaths in EGPA patients are directly attributed to cardiac involvement and occur mainly within the first few months following diagnosis [6].

The most severe form of cardiac involvement is cardiomyopathy secondary to endomyocardial eosinophilic infiltration (i.e., Loeffler endocarditis), causing impaired left ventricular function
at diagnosis [6]. Other features of heart involvement may include valvular insufficiencies, eosinophilic coronaritis, constrictive or acute pericarditis, conduction defects, ventricular or supraventricular arrhythmias, intraventricular thrombosis, and sudden death [2,6,8].

Causes of cardiac damage in EGPA include initially direct damage by eosinophilic myocardial infiltration with consequent necrosis. Then, an ischemic mechanism may be involved; this induces inflammation and thrombotic obstruction of epicardial coronary arteries or perforating myocardial vessels and the development of fibrosis on the endocardium, myocardium, and tendon cords. Finally, systemic inflammation and steroid therapy may favor the onset of other cardiovascular risk factors such as diabetes, dyslipidemia, hypertension, and obesity [8].

Our patient had a biventricular cardiomyopathy with a hypokinetic-dilated phenotype and a thromboembolic status (intraventricular thrombus, pulmonary embolism, uterine and gonadic vein thrombus). So, hypereosinophilia must have been responsible for thromboembolic status. In the present case, a particular sign of severity and adverse outcomes was represented by intra-cardiac thrombus, favored by several factors inducing the alteration of all three components of the Virchow triad. In particular, severe ventricular dysfunction favors stasis, and eosinophil and eosinophil-derived products can cause endothelial damage and favor a pro-thrombogenic state through different mechanisms [6,9].

ANCA autoantibodies, usually against myeloperoxidase, are detectable in only ~40% of EGPA cases [2,5]. EGPA patients with negative ANCA, as in the case report, have more severe eosinophilic lung and heart involvement [6]. In particular, EGPA patients with negative ANCA demonstrated a higher inflammatory cardiac disease (coronary arteritis, myocarditis, and pericarditis), leading to a worse prognosis than those with positive ANCA [8].

Because of the possible cardiac involvement, the initial evaluation and follow-up of patients with EGPA, requires the measurement of serum troponins (TnIs) and brain natriuretic peptides (BNPs) [10]. Indeed, although these markers are not specific, they are high in patients with EGPA and cardiac involvement. Also, they are helpful markers for patient follow-up, prognostic assessment, and identification of possible adverse cardiac events. BNP levels increase in ventricular pressure or volume overload and, therefore, in case of heart failure. Instead, TnI levels rise due to myocardial injury and, in the context of EGPA, may increase because of arthritis or myocarditis [10]. Therefore, both BNP and TnI levels may be helpful as markers to identify cardiac involvement and as a marker for patient monitoring.

Concerning instrumental diagnostic tools, cardiac alterations depend on the type of heart involvement. In the current case, the EKG showed diffuse ST-T alterations with poor r-wave
progression in precordial leads. Other alterations include first-degree atrioventricular block, atrial dilation, ventricular hypertrophy, incomplete BBDx, poor R-wave progression in precordial leads, and negative T-waves.

A structured imaging assessment is necessary to identify the impaired cardiac function and endomyocardial abnormalities in EGPA [6]. The trans-thoracic echocardiogram may reveal left ventricular hypertrophy, left atrial dilation, right ventricular dilation, pericardial effusion, and a paradigmatic sign represented by an apical intraventricular thrombus [9]. Instead, the most common CMR findings are sub-endocardial LGE and left ventricular dilation with globally reduced ejection fraction. Finally, although more invasive, endomyocardial biopsy represents the gold standard for diagnosing eosinophilic infiltration of the cardiac tissue in addition to endocardial fibrosis, intramural thrombosis, small vessel inflammation, and thrombosis [6].

EGPA diagnosis is based on the following criteria coded by the ACR/EULAR 2022 Guidelines (a score ≥6 is required) [3]: obstructive airway disease (+3); nasal polyps (+3); mononeuritis multiplex (+1); blood eosinophil count ≥ 1×10⁹/L (+5); extravascular eosinophilic-predominant inflammation on biopsy (+2); positive test for cytoplasmic anti-neutrophil cytoplasmic antibodies (cANCA) or antiproteinase 3 (anti-PR3) antibodies (-3); hematuria (-1).

In the present case report, clinical and laboratory criteria supported the diagnosis (score = 12), so the biopsy was unnecessary, even considering the intra-cardiac thrombus and the high thrombotic phenotype.

Established treatments for EGPA include glucocorticosteroid and cyclophosphamide, which usually determine a significant reduction of eosinophils and clinical improvement. In addition, recombinant humanized antibodies like Omalizumab and Mepolizumab or chimeric monoclonal antibody Rituximab may be used as an add-on therapy with steroid-sparing and in cases of refractory or relapsing disease [2]. In particular, Omalizumab targets the high-affinity receptor binding site on free IgE, preventing allergen-specific IgE from attaching to FcεRI on mast cells and basophils (with a consequent downregulation of FcεRI and inhibition of mediator release) [11]. Also, IL-5 is highly expressed in patients with EGPA; therefore, mepolizumab (anti-IL-5) is also a valid therapy for EGPA since binds to free IL-5 preventing the association between IL-5 and IL-5 receptors on the surface of eosinophils and basophils (reducing their activation) [12]. Finally, Rituximab may be used to target B-lymphocytes’ surface CD20 antigen, resulting in B-cell suppression [13]. In our patient, we also excluded
the FIP1L1-PDGFRα mutation, a hypereosinophilia genetic variant associated with beneficial therapy with imatinib [14].

Considering the severe and multi-organ involvement, anti-inflammatory/immunosuppressant therapy with glucocorticoids and cyclophosphamide was started, in addition to guideline-directed medical treatment for heart failure and therapeutic dose anticoagulation. We observed a reduction of blood eosinophils with a simultaneous improvement of respiratory and neurological involvement. However, despite optimizing treatment for heart failure, no significant improvement in biventricular function was observed (persistence of LVEF < 35%); this finding, in addition to extended LGE at CMR, suggested poor reversibility of the cardiomyopathy with medical therapy. Therefore, the implantation of a subcutaneous defibrillator for primary prevention of sudden cardiac death was necessary, as recommended by the 2022 ESC guidelines [4].

Conclusions
EGPA may heterogeneously involve the cardiovascular system and lead to severe complications. Therefore, a high clinical suspicion is necessary to diagnose this multi-faced vasculitis, to start treatment promptly, and to avoid clinical worsening and complications.

References
Figure 1. Admission electrocardiogram showing low QRS voltages in the peripheral leads, normal atrioventricular and intraventricular conduction, poor r-wave progression in the precordial leads, and diffuse repolarization abnormalities.

Figure 2. Transthoracic color Doppler echocardiogram showing left ventricle apical thrombus and pericardial effusion.

Figure 3. CMR showing infra-myocardial LGE and pleuropericardial effusion.